Prometheus Research appoints vp of sales
Prometheus Research, a US provider of database software for biomedical researchers and industry, has named Peter Harker as its new vice president of sales.
Harker takes responsibility for developing and managing sales for the company's Research Informatics biomedical software services and new HTSQL database software for industry.
Prior to joining Prometheus, Harker held a variety of sales roles, most recently as managing director for BondDesk, a provider of software and services for fixed income trading.
You may also like
Finance
![Fulcrum Therapeutics merges with Slate Medicines in $245m-backed deal]()
Fulcrum Therapeutics merges with Slate Medicines in $245m-backed deal
The all-stock merger sees Fulcrum rebuild following its pociredir discontinuation, with the combined entity focusing on SLTE-1009 — a monoclonal antibody in development for migraine and headache disorders — funded into 2029
Finance
![Prescient completes integration of Uptake and Dolon under single global brand]()
Prescient completes integration of Uptake and Dolon under single global brand
Prescient Healthcare Group has completed the integration of Uptake and Dolon, creating a 550-strong life sciences consultancy spanning commercial strategy, medical affairs, competitive intelligence and market access
Finance
![AlzeCure receives $12m upfront as NeuroRestore Alzheimer's platform licensing deal with QuantumCell closes]()
AlzeCure receives $12m upfront as NeuroRestore Alzheimer's platform licensing deal with QuantumCell closes
The payment — comprising $7m in licence fees and $5m direct investment — kicks off a collaboration worth more than $2.2bn in potential milestones, with QuantumCell assuming global rights to ACD856 and the NeuroRestore platform
Manufacturing
![DNA Script and GE Healthcare awarded $26m ARPA-H funding to scale cell-free DNA bioproduction]()
DNA Script and GE Healthcare awarded $26m ARPA-H funding to scale cell-free DNA bioproduction
The pair will combine DNA Script's EDS technology with GE HealthCare's DNA scaling technology to create a faster, more flexible manufacturing process for cell-free DNA as the use of personalised and time-sensitive genetic medicines grows
